Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for
enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scRNA/TCR-seq …

Improving the efficacy of immune checkpoint therapies will require a better understanding of
how immune cells are recruited and sustained in tumors. Here, we used the …

An improved understanding of the anti-tumor CD8+ T cell response after checkpoint
blockade would enable more informed and effective therapeutic strategies. Here we …

Immune checkpoint therapy (ICT) results in durable responses in individuals with some
cancers, but not all patients respond to treatment. ICT improves CD8+ cytotoxic T …

In tumors, a subset of CD8+ T cells expressing the transcription factor TCF-1 drives the
response to immune checkpoint blockade. We examined the mechanisms that maintain …

The antitumor action of immune checkpoint blockade (ICB) is primarily mediated by CD8+ T
cells. How sensitivity to ICB varies across CD8+ T cell subsets and clonotypes and the …

INTRODUCTION Cancer immunotherapies that target tumor-specific T cells have benefited
many cancer patients, but the clinical efficacy varies greatly among different cancer types …

Cancer immunotherapies have shown sustained clinical responses in treating non-small-
cell lung cancer,–, but efficacy varies and depends in part on the amount and properties of …

Checkpoint blockade mediates a proliferative response of tumor-infiltrating CD8+ T
lymphocytes (TILs). The origin of this response has remained elusive because chronic …

A paradigm shift in the understanding of the exhausted CD8+ T cell (Tex) lineage is
underway. Originally thought to be a uniform population that progressively loses effector …